Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

NCT00736749 · tracked via the Priya Life Science Israel tracker

Sponsor

Children's Oncology Group

Phase

Observational

Started

2008-07-17

Last updated

2026-04-06

Condition(s) studied

Hematopoietic Cell Transplantation RecipientLeukemiaSolid Tumor

Investigational drug(s) / intervention(s)

Assessment of Therapy ComplicationsQuestionnaire Administration

Assessment of Therapy Complications: Complete patient response form and Health Status Update Form

Questionnaire Administration: Complete patient response form, Health Status Update Form (called the "Keep in Touch" form), and Quality of Life Questionnaire (PROMIS)

Study summary

This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * The patient must reside in the U.S. on the date of enrollment to ALTE05N1 * All patients and/or their parents or legal guardians must sign a written informed consent * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Primary outcome measure(s)

Percentage of patients enrolled — Up to 20 years
Percentage of patients in which long-term (20+ years) contact is maintained — Up to 20 years
Percentage of eligible patients located who were lost to follow-up — Up to 20 years
Percentage of located patients enrolled — Up to 20 years
Differences between participants and non-participants will be examined annually, in terms of demographic (age, sex, ethnicity) and clinical characteristics (primary diagnosis, therapeutic protocol, time since diagnosis, treating institution).
Collection of protocol-specific outcome data — Up to 20 years
Methods of statistical analysis to be used are those appropriate for analysis of cohort studies. Poisson regression (piece-wise exponential models) and Cox regression will be the primary methods of risk-factor analysis. When comparing study cohort with national rates, Poisson regression will be used. When the comparison is internal (ie, no use of national standard rates), Cox regression will be used.
Collection of cumulative therapeutic exposure data — Up to 20 years

Trial sites (164)

Facility	City	Region
Children's Hospital of Alabama	Birmingham	Alabama
University of Alabama at Birmingham Cancer Center	Birmingham	Alabama
USA Health Strada Patient Care Center	Mobile	Alabama
Phoenix Childrens Hospital	Phoenix	Arizona
The University of Arizona Medical Center-University Campus	Tucson	Arizona
Arkansas Children's Hospital	Little Rock	Arkansas
University of Arkansas for Medical Sciences	Little Rock	Arkansas
Kaiser Permanente Downey Medical Center	Downey	California
City of Hope Comprehensive Cancer Center	Duarte	California
Loma Linda University Medical Center	Loma Linda	California
Miller Children's and Women's Hospital Long Beach	Long Beach	California
Children's Hospital Los Angeles	Los Angeles	California
Cedars Sinai Medical Center	Los Angeles	California
Mattel Children's Hospital UCLA	Los Angeles	California
Valley Children's Hospital	Madera	California
Kaiser Permanente-Oakland	Oakland	California
Children's Hospital of Orange County	Orange	California
Lucile Packard Children's Hospital Stanford University	Palo Alto	California
University of California Davis Comprehensive Cancer Center	Sacramento	California
Rady Children's Hospital - San Diego	San Diego	California
UCSF Medical Center-Parnassus	San Francisco	California
UCSF Medical Center-Mission Bay	San Francisco	California
Children's Hospital Colorado	Aurora	Colorado
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center	Denver	Colorado
Connecticut Children's Medical Center	Hartford	Connecticut
Yale University	New Haven	Connecticut
Alfred I duPont Hospital for Children	Wilmington	Delaware
MedStar Georgetown University Hospital	Washington D.C.	District of Columbia
Children's National Medical Center	Washington D.C.	District of Columbia
Broward Health Medical Center	Fort Lauderdale	Florida
Lee Memorial Health System	Fort Myers	Florida
Golisano Children's Hospital of Southwest Florida	Fort Myers	Florida
University of Florida Health Science Center - Gainesville	Gainesville	Florida
Nemours Children's Clinic-Jacksonville	Jacksonville	Florida
Miami Cancer Institute	Miami	Florida
Florida Hospital Orlando	Orlando	Florida
Arnold Palmer Hospital for Children	Orlando	Florida
Nemours Children's Clinic - Orlando	Orlando	Florida
UF Cancer Center at Orlando Health	Orlando	Florida
Nemours Children's Hospital	Orlando	Florida

+ 124 more sites — see the full list on the official registry below.

More Children's Oncology Group trials in Israel

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) Recruiting

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Recruiting

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma Active, not recruiting

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss Recruiting

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) Recruiting

Other trials for the same condition

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) Recruiting

A Study of ASP3082 in Adults With Advanced Solid Tumors Recruiting

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors Recruiting

A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia Active, not recruiting

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT00736749 on ClinicalTrials.gov ↗ ← All trials in Israel